Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 29, Issue 24, 2011, Pages 3307-3315

  Sequist, Lecia V ^a   Von Pawel, Joachim ^c   Garmey, Edward G ^b   Akerley, Wallace L ^e   Brugger, Wolfram ^d   Ferrari, Dora ^b   Chen, Yinpu ^b   Costa, Daniel B ^a   Gerber, David E ^f   Orlov, Sergey ^g   Ramlau, Rodryg ^h   Arthur, Susan ⁱ   Gorbachevsky, Igor ^j   Schwartz, Brian ^b   Schiller, Joan H ^f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ARQULE INC   (United States)

^c Asklepios Fachkliniken   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF UTAH   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^h POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

ⁱ ICON PLC   (United Kingdom)

^j DAIICHI SANKYO INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; PLACEBO; SCATTER FACTOR RECEPTOR; TIVANTINIB; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FATALITY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLACEBOS; PROTO-ONCOGENE PROTEINS C-MET; PYRROLIDINONES; QUINAZOLINES; QUINOLINES; RECEPTORS, GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 80051974548     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.0570     Document Type: Article

References (28)

1. Sandler A., Gray R., Perry M.C., et al: Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
2. Scagliotti G.V., Parikh P., Von Pawel J., et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
3. Lynch T.J., Bell D.W., Sordella R., et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
4. Mok T.S., Wu Y.L., Thongprasert S., et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
5. Birchmeier C., Birchmeier W., Gherardi E., et al: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925, 2003 (Pubitemid 37493640)
6. Comoglio P.M., Giordano S., Trusolino L.: Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504-516, 2008 (Pubitemid 351767118)
7. Cappuzzo F., Jänne P.A., Skokan M., et al: MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 20:298-304, 2009
8. Cappuzzo F., Marchetti A., Skokan M., et al: Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 27:1667-1674, 2009
9. Go H., Jeon Y.K., Park H.J., et al: High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 5:305-313, 2010
10. Engelman J.A., Zejnullahu K., Mitsudomi T., et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043, 2007 (Pubitemid 46799492)
11. Bean J., Brennan C., Shih J.Y., et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932-20937, 2007
12. Turke A.B., Zejnullahu K., Wu Y.L., et al: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17:77-88, 2010
13. Munshi N., Jeay S., Li Y., et al: ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9:1544-1553, 2010
14. Yap T.A., Frentzas S., Tunariu N., et al: Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition. J Clin Oncol 27:151s, 2009 (abstr 3523)
15. Laux I., Goldman J., Just R., et al: Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib. J Clin Oncol 27:158s, 2009 (abstr 3549)
16. Therasse P., Arbuck S.G., Eisenhauer E.A., et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
17. Oken M.M., Creech R.H., Tormey D.C., et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982 (Pubitemid 13149996)
18. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
19. Cappuzzo F., Hirsch F.R., Rossi E., et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005 (Pubitemid 40812628)
20. Pao W., Miller V., Zakowski M., et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004 (Pubitemid 39209661)
21. Rosell R., Moran T., Queralt C., et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967, 2009
22. Massarelli E., Varella-Garcia M., Tang X., et al: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13:2890-2896, 2007 (Pubitemid 46849563)
23. Jackman D.M., Miller V.A., Cioffredi L.A., et al: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials. Clin Cancer Res 15:5267-5273, 2009
24. Gangarosa L.M., Sizemore N., Graves-Deal R., et al: A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J Biol Chem 272:18926-18931, 1997 (Pubitemid 27318245)
25. Sizemore N., Cox A.D., Barnard J.A., et al: Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor-related peptides. Gastroenterology 117:567-576, 1999 (Pubitemid 29409242)
26. Long I.S., Han K., Li M., et al: Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo. Mol Cancer Res 1:393-401, 2003 (Pubitemid 36437925)
27. Smolen G.A., Sordella R., Muir B., et al: Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 103:2316-2321, 2006
28. Kim E.S., Hirsh V., Mok T., et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008